Common Stock, Shares, Outstanding of Adaptimmune Therapeutics PLC from 30 Jun 2014 to 30 Jun 2025

Taxonomy & unit
us-gaap: shares
Description
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Summary
Adaptimmune Therapeutics PLC quarterly Common Stock, Shares, Outstanding in shares history and change rate from 30 Jun 2014 to 30 Jun 2025.
  • Adaptimmune Therapeutics PLC Common Stock, Shares, Outstanding for the quarter ending 30 Jun 2025 was 1,590,309,546, a 3.7% increase year-over-year.
Source SEC data
View on sec.gov
Common Stock, Shares, Outstanding, Quarterly (shares)
Common Stock, Shares, Outstanding, YoY Quarterly Change (%)

Adaptimmune Therapeutics PLC Quarterly Common Stock, Shares, Outstanding (shares)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 1,590,309,546 +56,088,942 +3.7% 30 Jun 2025 10-Q 13 Aug 2025 2025 Q2
Q1 2025 1,547,093,808 +14,118,930 +0.92% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 1,535,653,620 +172,645,518 +13% 31 Dec 2024 10-Q 13 Aug 2025 2025 Q2
Q3 2024 1,534,220,604 +172,625,568 +13% 30 Sep 2024 10-Q 13 Nov 2024 2024 Q3
Q2 2024 1,534,220,604 +182,392,560 +13% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 1,532,974,878 +539,274,918 +54% 31 Mar 2024 10-Q 15 May 2024 2024 Q1
Q4 2023 1,363,008,102 +375,898,212 +38% 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 1,361,595,036 +378,875,100 +39% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 1,351,828,044 +375,068,520 +38% 30 Jun 2023 10-Q 09 Aug 2023 2023 Q2
Q1 2023 993,699,960 +52,833,954 +5.6% 31 Mar 2023 10-Q 12 May 2023 2023 Q1
Q4 2022 987,109,890 +58,561,956 +6.3% 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 982,719,936 +45,670,116 +4.9% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 976,759,524 +40,522,398 +4.3% 30 Jun 2022 10-Q 04 Aug 2022 2022 Q2
Q1 2022 940,866,006 +8,048,838 +0.86% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 928,547,934 -207,024 -0.02% 31 Dec 2021 10-K 06 Mar 2023 2022 FY
Q3 2021 937,049,820 +8,524,410 +0.92% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 936,237,126 +8,568,180 +0.92% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 932,817,168 +152,302,828 +20% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 928,754,958 +297,751,390 +47% 31 Dec 2020 10-K 14 Mar 2022 2021 FY
Q3 2020 928,525,410 +297,572,674 +47% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 927,668,946 +296,996,368 +47% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 780,514,340 +152,219,638 +24% 31 Mar 2020 10-Q 14 May 2020 2020 Q1
Q4 2019 631,003,568 +3,549,298 +0.57% 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 630,952,736 +3,730,660 +0.6% 30 Sep 2019 10-Q 06 Nov 2019 2019 Q3
Q2 2019 630,672,578 +64,176,178 +11% 30 Jun 2019 10-Q 01 Aug 2019 2019 Q2
Q1 2019 628,294,702 +63,434,742 +11% 31 Mar 2019 10-Q 06 May 2019 2019 Q1
Q4 2018 627,454,270 +65,334,936 +12% 31 Dec 2018 10-K 27 Feb 2020 2019 FY
Q3 2018 627,222,076 +65,102,742 +12% 30 Sep 2018 10-Q 06 Nov 2018 2018 Q3
Q2 2018 566,496,400 +5,393,274 +0.96% 30 Jun 2018 10-Q 02 Aug 2018 2018 Q2
Q1 2018 564,859,960 +45,883,530 +8.8% 31 Mar 2018 10-Q 09 May 2018 2018 Q1
Q4 2017 562,119,334 +137,344,242 +32% 31 Dec 2017 10-K 27 Feb 2019 2018 FY
Q3 2017 562,119,334 +137,407,434 +32% 30 Sep 2017 10-Q 02 Nov 2017 2017 Q3
Q2 2017 561,103,126 +136,391,226 +32% 30 Jun 2017 10-Q 03 Aug 2017 2017 Q2
Q1 2017 518,976,430 +94,264,530 +22% 31 Mar 2017 10-Q 10 May 2017 2017 Q1
Q4 2016 424,775,092 +63,192 +0.02% 31 Dec 2016 10-K 15 Mar 2018 2017 FY
Q3 2016 424,711,900 30 Sep 2016 10-Q 10 Nov 2016 2016 Q3
Q2 2016 424,711,900 0 0% 30 Jun 2016 10-Q 08 Aug 2016 2016 Q2
Q1 2016 424,711,900 31 Mar 2016 10-Q 12 May 2016 2016 Q1
Q4 2015 424,711,900 31 Dec 2015 10-K 13 Mar 2017 2016 FY
Q2 2015 424,711,900 +243,341,800 +134% 30 Jun 2015 10-K 13 Mar 2017 2016 FY
Q2 2014 181,370,100 30 Jun 2014 8-K 08 Jul 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.